- Home
- RDI vs VYNE Comparison
RDI vs VYNE Comparison
Compare RDI & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDI
- VYNE
- Stock Information
- Founded
- RDI 1937
- VYNE 2003
- Country
- RDI United States
- VYNE United States
- Employees
- RDI N/A
- VYNE N/A
- Industry
- RDI Movies/Entertainment
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- RDI Consumer Discretionary
- VYNE Health Care
- Exchange
- RDI Nasdaq
- VYNE Nasdaq
- Market Cap
- RDI 30.1M
- VYNE 35.7M
- IPO Year
- RDI N/A
- VYNE 2018
- Fundamental
- Price
- RDI $1.25
- VYNE $1.85
- Analyst Decision
- RDI Hold
- VYNE Strong Buy
- Analyst Count
- RDI 1
- VYNE 2
- Target Price
- RDI $2.40
- VYNE $6.88
- AVG Volume (30 Days)
- RDI 42.0K
- VYNE 224.4K
- Earning Date
- RDI 05-14-2025
- VYNE 05-08-2025
- Dividend Yield
- RDI N/A
- VYNE N/A
- EPS Growth
- RDI N/A
- VYNE N/A
- EPS
- RDI N/A
- VYNE N/A
- Revenue
- RDI $210,527,000.00
- VYNE $501,000.00
- Revenue This Year
- RDI $11.97
- VYNE N/A
- Revenue Next Year
- RDI $6.40
- VYNE N/A
- P/E Ratio
- RDI N/A
- VYNE N/A
- Revenue Growth
- RDI N/A
- VYNE 18.16
- 52 Week Low
- RDI $1.17
- VYNE $1.44
- 52 Week High
- RDI $1.89
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- RDI 45.11
- VYNE 53.21
- Support Level
- RDI $1.18
- VYNE $1.76
- Resistance Level
- RDI $1.28
- VYNE $1.93
- Average True Range (ATR)
- RDI 0.08
- VYNE 0.16
- MACD
- RDI 0.00
- VYNE 0.06
- Stochastic Oscillator
- RDI 25.00
- VYNE 83.67
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial, and live theater assets.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.